Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Prostatic Neoplasms 9Glioblastoma 9Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Brain Neoplasms 6Glioma 5Breast Neoplasms 5Oligodendroglioma 4Neoplasm Metastasis 4Multiple Myeloma 4Colorectal Neoplasms 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Neoplasms 3Meningioma 3Medulloblastoma 3Gliosarcoma 3Glioma, Subependymal 3Ependymoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Platinum-Refractory Fallopian Tube Carcinoma 2Pinealoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Hematologic Neoplasms 2

Interventions

Taxes 2Paclitaxel 2Magnetic Resonance Spectroscopy 2olaparib 1liposomal doxorubicin 1copanlisib 1Topotecan 1Specimen Handling 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Bevacizumab 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Platinum-Refractory Fallopian Tube Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gynecologic

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡